Activist Investor
Sitting on Lows, Waiting for Turnaround
The Activist Investor goal is to buy shares before they soar: investing in activist campaign stocks that have been sold off to their lowest levels… then benefit as these companies begin to turn around and prosper.
Read More …
![](https://members.porterandcompanyresearch.com/wp-content/uploads/2024/06/GettyImages-1434664777.jpg)
Shock Value
This promising producer of next-generation digital and power devices caught the eye of an activist investor who is pushing hard to get the company to turn the billions it invested in new plants into exponential revenue growth.
Read More …
If Vans Gets Its Groove Back, VFC Shares Will Rise
With the share price down and with a handful of catalysts likely to drive the price higher, we provide an update on V.F. Corporation – and look at three other stocks in the portfolio as well: OneSpan, Orthofix Medical, and Mercury Systems.
Read More …
![](https://members.porterandcompanyresearch.com/wp-content/uploads/2024/04/GettyImages-1462199205-scaled.jpg)
Protecting Digital Data
This cybersecurity and digital-documents company has been the target of an activist since 2018 – now steady progress is about to show up in the financials and drive shares higher.
Read More …
Maintaining Patience As Volatility Rules
The Activist Investor portfolio continues to ride the waves of volatility. This update reports on those up and down movements and on some exciting things that have happened across all our stocks.
Read More …
![](https://members.porterandcompanyresearch.com/wp-content/uploads/2024/02/iStock-678024880.jpg)
Two Brothers, One Multibillion-Dollar Shoe
While this company may not be familiar to many people, its iconic brands certainly are. But because of corporate missteps, the owner of these gear and apparel makers has hit hard times — which we now see as an opportunity
Read More …
Action to Take: Buy Shares of MRCY
Action to Take: Buy Shares of Mercury Systems (MRCY) On February 6, after the market closed, Mercury Systems (Nasdaq: MRCY) reported earnings for its second quarter 2024 fiscal year – for the period ending December 2023. As is often the case with companies in a turnaround mode, the results were not good. In fact, company
Read More …
Action to Take: Sell Catalent at a Profit
On February 5, drug manufacturer Catalent (NYSE: CTLT) announced it would sell itself to Novo Nordisk (NYSE: NVO) for $63.50 per share in cash – about $11.5 billion in total. This share price is a 17% premium to the prior closing price of $54.51 on Friday, February 2, and an increase of 40% since we
Read More …
![](https://members.porterandcompanyresearch.com/wp-content/uploads/2024/01/GettyImages-1390278572.jpg)
This Is Spinal Tap
In this issue, we focus on a medical-device company that specializes in both orthopedic and spinal products used by doctors and surgeons across the globe. A mismanaged merger and other changes in strategy have sent the stock to record lows. Now, with an activist investor involved, we see good things happening for this company.
Read More …